Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXJ683)

Drug Name

KY1044 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Inducible T-cell costimulator (ICOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JTX-2011	DMGXTOP	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
XmAb23104	DMK9XUQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
MEDI-570	DMCJFLS	Systemic lupus erythematosus	4A40.0	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inducible T-cell costimulator (ICOS)	TTE5VP6	ICOS_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03829501) Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Kymab.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Xencor.
5	B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4.